OHSU in the news

Switching TNF inhibitors rare, delayed in AS despite inefficacy

Healio March 17, 2020
Atul Deodhar, M.D., reports 22% of patients with the chronic joint inflammation condition ankylosing spondylitis (AS) discontinue treatment with tumor necrosis factor (TNF) inhibitors after a year due to drug inefficacy or adverse events.
See more stories